Tandem Meetings 2023 | Patient selection for SCT & recent updates in strategies to reduce GvHD & relapse following SCT

Dietger Niederwieser, MD, University of Leipzig, Leipzig, Germany, comments on patient selection for stem cell transplantation (SCT), highlighting recent updates in efforts to reduce the incidence of graft-versus-host disease (GvHD) and relapse following SCT. Prof. Niederwieser explains that SCT is the best treatment strategy in some patient groups including patients with intermediate- or high-risk acute myeloid leukemia (AML). Prof. Niederwieser then emphasizes the importance of considering age and comorbidities when selecting patients for transplant, highlighting that recent advances have allowed older patients or patients with comorbidities to access SCT. At the Tandem meetings, a pre-clinical study demonstrated the potential of targeting RIP1 to treat GvHD whilst maintaining the graft-versus-leukemia (GvL) effect, and another study using a radiolabelled antibody in combination with SCT showed superiority over conventional therapy in terms of overall survival (OS). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.